Click here to participate
|
|
|
|
|
|
|
|
|
| | By checking the box, you indicate that you have read and understood the MSD Privacy Policy that states "Merck Sharp & Dohme (I.A.) LLC (“MSD”) is committed to protecting the security and privacy of your personal information. Our Privacy Notice will help you understand how we collect, use, and disclose your personal information. We ensure that our policies and practices with respect to collection, use, access, retention, disclosure, security and transfer of personal information comply with Republic Act No. 10173 or the “Data Privacy Act of 2012”, its Implementing Rules and Regulations, and such other applicable laws on data privacy protection and security. By submitting your personal information, you consent to the collection, processing, use, access, storage and transfer of your personal information in accordance with and agree to be bound by the terms stated in this Notice." MSD privacy policy can be accessed at http://www.msd.com.ph/responsibility/pages/privacy.aspx | |
|
|
|
|
|
| | MSD will collect your personal information for the purpose of providing you with information about MSD’s products, services and/or programs, communicating information about our products through our professional representatives, websites, e-mails, call centers, postal mail and other channels, including promotional and other marketing communications; symposia, conferences, and other scientific and educational programs; and for such other purposes that may be agreed between you and us and/or may be required by law. | |
|
|
|
|
|
|
|
|
|
|
|
| | For most of the following questions, please think about typical cancer cases.
Please enter your facility/ hospital | |
|
|
|
|
|
|
|
| | Q1. Please choose the statement that best describes how the treatment planning approach for cancer patients at your facility compares with the survey’s definition of multidisciplinary treatment planning. | |
|
|
|
|
|
| | Q2. What is the multidisciplinary treatment planning approach for cancer patients called at your facility? | |
|
|
|
|
|
|
|
| | Q3. Once a patient is definitively diagnosed for cancer, would you describe the multidisciplinary treatment planning as prospective? | |
|
|
|
|
|
| | Q4. How often do those involved in multidisciplinary treatment planning for cancer cases meet either in-person or virtually, to discuss the case? | |
|
|
|
|
|
| | Q5. Are cancer patients invited to participate in treatment planning meetings with the multidisciplinary cancer care team? | |
|
|
|
|
|
| | Q6. Why aren’t patients invited? (Check all that apply) | |
|
|
|
|
|
| | Q7. Which best describes the physicians that participate in multidisciplinary treatment planning discussions at your facility about cancer patients? | |
|
|
|
|
|
| | Q8. Does your facility/hospital have a formal written policy or standard operating procedures for providing multidisciplinary treatment planning? | |
|
|
|
|
|
|
|
|
|
|
|